Mammoscintigraphy
- Article Author:
- Logan Ranzenberger
- Article Editor:
- Kristin Booth
- Updated:
- 6/21/2020 8:48:01 PM
- For CME on this topic:
- Mammoscintigraphy CME
- PubMed Link:
- Mammoscintigraphy
Introduction
Breast cancer is increasing in incidence and is one of the leading types of cancer. Once thought to be mostly a disease of elderly females, there is an increase in the incidence of breast cancer in women during their third and fourth decades of life. With increasing awareness, screening has become more prevalent, which in turn has increased the overall number of positive findings. Additionally, post-treatment monitoring increases with an overall increase in studies and survival rates. In an effort to decrease the morbidity and mortality of breast cancer, technological advances in breast imaging have been developed and are continuing to expand in order to detect breast cancers earlier. Methods of examination for breast cancer include self physical examination, physician physical examination, mammogram, tomography, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET). Another less commonly known and rarely used modality is scintimammography or mammoscintigraphy. Scintimammography is a type of nuclear medicine imaging, which has been considered adjuvant to mammography specifically for cases containing post-surgical changes, indeterminate mammogram findings, post neoadjuvant chemotherapy follow-up, and suspected multifocal disease. MRI of the breast has largely taken the place of scintimammography because it can provide similar information and more such as a high-quality preoperative evaluation. Currently, clinicians have not decided on definite indications for scintimammography, resulting in many studies evaluating its utility.[1][2][3][4]
Studies have attempted to define the importance of scintimammography through comparison of statistical data, including positive predictive values, false negatives, and false positives. The positive predictive value is low for mammograms, given the higher rates of false positives, but when combined with another modality, the positive predictive value will increase, which improves patient care and satisfaction overall.
Breast malignancies have been shown to have increased uptake of radiopharmaceuticals as compared to normal breast parenchyma. The diagnostic evaluation consists of intravenous injection of technetium 99m sestamibi (technetium 99m - DMSA or technetium 99m MDP can also be used, but are less sensitive) with subsequent imaging of the breasts.[5]
Anatomy and Physiology
Normal distribution of technetium 99m sestamibi (the most commonly used radiopharmaceutical for scintimammography) is the salivary glands, thyroid, myocardium, liver, and gallbladder.
Any uptake of radiopharmaceutical greater than the average breast parenchyma is suspicious for malignancy. If the breast demonstrates mild, homogenous uptake of the radiopharmaceutical, it is considered a normal study. Patchy, widespread uptake likely is not indicative of malignancy. Evaluation of the axilla is important for the interpretation of potential metastasis to axillary lymph nodes in the presence of an ipsilateral focal area of increased uptake suggesting primary malignancy. Axillary folds will demonstrate increased uptake as an artifact and should be considered normal, but can be a pitfall and lateral imaging should be used to identify its superficial location and linear appearance.[6]
Indications
Indications for scintimammography are debated given that MRI is currently the more preferred modality for similar indications; however, the most commonly stated reasons scintimammography is performed include equivocal, suspicious, or difficult to interpret mammograms and potential multifocal breast cancer. Additionally, patients with breast implants, axillary lymph node metastasis of an adenocarcinoma of unknown primary origin, and monitoring response to neoadjuvant chemotherapy.[7][8][9][10]
Contraindications
Contraindications for scintimammography are also currently being debated, with most being relative contraindications. Pregnant or lactating women would be at high risk for the fetus and/or infant with exposure to radiation. Scintimammography should not be performed if there is a history of recent surgical intervention including cyst aspiration, fine needle aspiration, core needle biopsy, and excisional biopsy with suggestions of waiting 2 weeks for minor procedures and up to six weeks for major procedures. Appropriate delay in the examination is recommended to minimize the chances of false positives from increased uptake in the post-surgical reactive tissues. Examination during menses should also be avoided, as well as hypersensitivity to technetium 99m.[11]
Equipment
A standard scintillation camera with a low-energy, high-energy collimator is used. A symmetric 10% energy window is used, centered over the 140 keV photopeak of technetium 99m.[11]
Personnel
Radiologists, nuclear medicine physicians, nuclear medicine technicians, cyclotron engineers/workers, and scheduling departments are required to set up and execute obtaining a scintimammogram. All members of the team play a vital role in carrying out the task.
Preparation
No specific preparation is needed for the patient to be ready for a scintimammogram. A nuclear medicine technologist will be an asset to assist in the explanation and execution of the examination. It should be ensured that the patient is capable of lying prone on a hard surface with the arms extended above the head before the procedure is started. The patient should wear a hospital gown and remove all clothing and jewelry.
Quality control should be performed according to the general guidelines by the Society of Nuclear Medicine on the scintillation camera.[11]
Technique
Imaging can be obtained in either planar and/or single-photon emission computed tomography. Intravenous injection with an indwelling catheter or butterfly needle of 20-30 mCi of technetium 99m into a vein of the upper extremity should be contralateral to the breast of concern. If there are suspicious bilateral findings, the lower extremity is then injected. Approximately 10 mL of saline flush should follow.
Prone positioning is appropriate with the non-pathological breast compressed against the table to prevent the dependent breast from the artifact of the contralateral breast. The arms are raised over the head with the head turned away from the detector to minimize artifact. The detector is placed against the patient.
The patient should be imaged 5 to 10 minutes after injection. Planar images to be obtained include prone lateral (including the breast, axilla and anterior chest wall), prone posterior oblique, and anterior upright/supine chest (includes bilateral breasts and axillae). If a marker is desired, it should be placed once the breast is in the proper position; otherwise, the abnormality could change in relation to the marker.
The breast tissue is near myocardial tissue, which is an organ that takes up technetium 99m, so post procession count subtraction should be obtained.[11]
Complications
The procedure is relatively non-invasive with few adverse effects; however, potential complications could include extravasation of radiopharmaceuticals and allergic reaction to radiopharmaceuticals. Extravasation of technetium 99m has not been shown to cause significant harmful effects to the tissue involved, and usually, surgical intervention would not be necessary. Allergic reactions to radiopharmaceuticals are rare, but if they happen or are at risk of occurring, appropriate steps are given by the American College of Radiology, which includes preparation with corticosteroids and antihistamines as well as emergent medications after the development of symptoms including epinephrine and labetalol.[12]
Clinical Significance
The main purpose of scintimammography is to increase the positive predictive value of breast cancer detection with imaging in order to decrease the overall cost and improve the patient experience by minimizing the number of negative breast biopsies. Currently, scintimammography is not commonly used because of MRI; as stated above, however, if additional research and discussion are performed to support its efficacy and use, it could be a valuable asset for the breast imaging world.[7][13][9]
Enhancing Healthcare Team Outcomes
Scintimammography is a diagnostic imaging modality using radiopharmaceuticals to identify breast malignancies. With limited complications, allergic reaction to radiopharmaceutical, and extravasation of radiopharmaceuticals, the most effective way of enhancing healthcare team outcomes is through identifying every step of the process and assigning a role to each team member. Prior to the patient arriving to the hospital or clinic for their examination, the following should be done:
- Appropriate scheduling should be provided to the patient to allow for optimal patient satisfaction.
- Screening for a history of recent surgeries, menstrual cycle, recent imaging with radiopharmaceuticals, history of contrast/radiopharmaceutical reactions, and personal medical history should be administered. Appropriate preparation for the patient should be overseen by the radiologist.
- The nuclear medicine technician should perform quality control according to the general guidelines by the Society of Nuclear Medicine on the scintillation camera.
- The radiologist should review the imaging for a better understanding of the case and ensure that the study meets the appropriate criteria.
- Radiopharmaceuticals of choice should be prepared and shipped within the appropriate timeframe to prevent radioactive decay.
When these roles have been assigned and are accomplished without interruption, the entire healthcare team, as well as the patient, have an overall better experience and outcomes, are more positive. Current Oxford CEBM levels of evidence would be at level 1.